SNP-610
- Generic Name
- SNP-610
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
Phase 2
Not yet recruiting
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2018-03-16
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Sinew Pharma Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT03468556
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath